Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.

Lyndon Marc Evans Barrie Chubb Samuel Joseph Paul MalkinSasha BerryJack LawsonBarnaby Hunt

Published in: Diabetes, obesity & metabolism (2022)

Based on a willingness-to-pay threshold of GBP 20 000 per QALY gained, once-weekly semaglutide 1 mg was projected to be highly cost-effective versus insulin aspart for the treatment of type 2 diabetes in the UK.

Keyphrases

type diabetes
cross sectional
climate change
metabolic syndrome
glycemic control
adipose tissue